idea
sequencespecif
gene
silenc
synthet
oligonucleotid
target
mrna
least
year
old
technic
advanc
made
chemic
synthesi
oligonucleotid
possibl
practic
step
could
taken
toward
implement
result
delug
experiment
data
varieti
system
employ
phosphorothio
ps
backbon
modif
much
ultim
unfortun
uninterpret
reason
uninterpret
somewhat
complic
ps
oligonucleotid
contain
sulfur
atom
substitut
nonbridg
oxygen
atom
phosphoru
oligonucleotid
chain
molecul
produc
phosphodiest
oligonucleotid
contain
linkag
ident
found
normal
dna
could
use
silenc
gene
express
either
tissu
cultur
vivo
sensit
nucleas
digest
especi
also
rapidli
clear
plasma
kidney
contrast
phosphorothio
degrad
rel
slowli
nucleas
also
clear
kidney
rel
slowli
lowaffin
bind
plasma
protein
predominantli
albumin
sulfur
immedi
beneath
oxygen
period
tabl
ps
linkag
retain
neg
charg
po
linkag
thu
bestow
properti
extrem
aqueou
solubl
importantli
biophys
behavior
ps
po
oligonucleotid
solut
govern
backbon
charg
sequenc
addit
ps
linkag
retain
properti
substrat
rnase
h
ubiquit
predomin
nuclear
enzym
cleav
mrna
strand
duplex
appar
function
natur
elimin
okazaki
fragment
ostens
permit
gene
silenc
occur
via
pseudocatalyt
mechan
requir
submicromolar
concentr
ps
oligonucleotid
efficaci
least
transfect
cell
employ
carrier
lipid
vehicl
practic
purpos
po
ps
oligonucleotid
elicit
rnase
h
activ
interestingli
whether
rnase
h
mechan
gene
silenc
correct
mount
evid
may
respons
small
percentag
total
gene
silenc
silenc
may
actual
occur
predomin
due
activ
enzym
slicer
function
cleav
mrna
strand
duplex
risc
complex
howev
despit
import
properti
ps
oligonucleotid
led
featur
sever
import
clinic
cancer
trial
side
chemic
modif
ps
oligonucleotid
biochem
fundament
differ
po
oligonucleotid
differ
signific
abil
hybrid
complementari
mrna
strand
greatli
diminish
respect
isosequenti
po
oligonucleotid
respect
offtarget
effect
greatli
enhanc
diminish
hybrid
reflect
lower
melt
temperatur
psoligomrna
duplex
directli
correl
diminish
antisens
activ
may
part
reason
clinic
trial
ps
oligonucleotid
success
discuss
although
clinic
import
aspect
studi
design
diseas
characterist
may
also
explain
observ
fortun
recent
develop
sugarmodifi
lock
nucleic
acid
lna
antisens
oligonucleotid
appear
solv
diminish
hybrid
problem
ps
oligonucleotid
lna
incorpor
ps
oligonucleotid
four
commonli
employ
two
molecular
terminu
may
rais
duplex
henc
potenti
gene
silenc
clinic
trial
lna
oligonucleotid
chronic
lymphocyt
leukemia
cll
current
underway
data
yet
avail
offtarget
effect
ps
oligonucleotid
fall
two
basic
categori
abil
bind
heparinbind
protein
immunostimulatori
properti
induc
splenomegali
blymphocyt
prolifer
cytokin
product
rodent
appear
particularli
sensit
phosphorothio
class
effect
neither
categori
offtarget
effect
dealt
extens
review
effect
rigor
control
particularli
experi
immunosuppress
mice
may
difficult
imposs
differenti
sequencespecif
effect
offtarget
effect
led
great
difficulti
interpret
experiment
data
previous
note
problem
compound
fact
extent
immunestimul
ps
oligonucleotid
without
cpg
motif
mous
differ
human
unfortun
mean
preclin
anim
model
employ
ps
oligonucleotid
may
littl
predict
valu
respons
clinic
trial
patient
nevertheless
despit
problem
extrem
interest
data
emerg
recent
larg
random
multicent
phase
iii
trial
antisens
oligonucleotid
particularli
melanoma
cll
trial
addit
provoc
phase
trial
cancer
form
basi
major
review
phase
trial
laterphas
trial
perform
popul
cancer
patient
discuss
substanti
evid
indic
cll
cell
silenc
may
lead
signific
cellular
apoptosi
therefor
random
phase
iii
trial
fludarabin
f
plu
cyclophosphamid
c
without
oblimersen
initi
patient
relaps
refractori
cll
total
patient
stratifi
random
accord
three
criteria
respons
vs
refractori
prior
fludarabin
therapi
number
prior
regimen
vs
durat
respons
last
therapi
month
vs
month
patient
requir
receiv
least
one
prior
chemotherapi
regimen
includ
least
two
cycl
fludarabin
use
standard
definit
patient
relaps
prior
treatment
fludarabin
achiev
least
pr
last
month
patient
achiev
least
pr
last
month
last
fludarabin
treatment
consid
refractori
fc
group
patient
receiv
fludarabin
intraven
iv
follow
cyclophosphamid
iv
day
oblimersenfc
group
patient
given
oblimersen
mgkgday
continu
iv
infus
day
fc
administ
dose
day
cycl
day
durat
six
cycl
administ
primari
end
point
studi
betweentreat
differ
proport
patient
achiev
cr
nodular
partial
respons
npr
clinic
equival
cr
heretofor
cr
npr
refer
cr
demograph
characterist
two
group
well
balanc
median
number
prior
treatment
regimen
group
three
previou
therapi
balanc
betweentreat
group
twenti
patient
oblimersenfc
group
achiev
cr
oppos
p
fc
group
moreov
cr
significantli
durabl
oblimersenfc
group
month
followup
durat
complet
remiss
fctreat
patient
month
wherea
median
reach
estim
exceed
month
patient
oblimersenfc
group
p
month
followup
oblimersenfc
patient
cr
remain
aliv
includ
five
remain
complet
remiss
eight
fctreat
patient
cr
three
aliv
year
three
relaps
maximum
benefit
seen
fludarabinesensit
patient
eg
pr
better
month
prior
fludarabin
treatment
popul
fourfold
increas
cr
rate
oblimersenfc
group
compar
fc
control
vs
p
year
followup
among
patient
achiev
respons
includ
complet
partial
respons
n
median
surviv
benefit
patient
oblimersenfc
group
hr
p
nonrespond
patient
differ
surviv
outcom
group
respect
nonhematolog
toxic
nausea
pyrexia
fatigu
primarili
grade
commonli
occur
affect
patient
oblimersenfc
group
fc
group
grade
occurr
nausea
pyrexia
fatigu
limit
vs
patient
patient
group
vs
patient
respect
importantli
popul
infect
immunosuppress
common
caus
death
incid
grade
neutropenia
vs
increas
addit
oblimersen
fc
regimen
grade
thrombocytopenia
frequent
oblimersenfc
group
associ
increas
incid
grade
bleed
event
vs
approxim
patient
oblimersen
administr
associ
firstcycl
reaction
cytokin
releas
without
tumor
lysi
data
demonstr
import
achiev
cr
longterm
surviv
cll
point
initi
contest
fda
although
oblimersen
date
yet
approv
indic
fda
current
reconsid
decis
basi
recent
report
surviv
data
doubt
oblimersen
silenc
express
tissu
cultur
abil
vivo
importantli
extent
silenc
actual
chemosensit
malign
cell
predict
matter
great
debat
far
antiapoptot
protein
present
vast
major
malign
cell
even
follicular
lymphoma
cell
bear
chromosom
transloc
produc
fuse
mrna
case
clear
whether
protein
necessari
suffici
mainten
neoplast
phenotyp
tumor
elev
express
protein
tumor
cell
may
mere
epiphenomenon
despit
document
clinic
correl
express
overexpress
protein
poor
prognosi
cancer
patient
tumor
blagosklonni
address
question
note
express
colorect
breast
lung
carcinoma
associ
increas
apoptot
index
lower
risk
distant
metastas
improv
prognosi
furthermor
concord
much
experiment
data
cell
line
may
resist
due
strong
select
establish
cell
cultur
overexpress
simpli
increas
resist
effect
undetect
tumor
cell
may
also
becom
resist
cytotox
therapeut
downregul
protein
apoptot
cascad
exampl
melanoma
downstream
whose
absenc
level
protein
express
would
appear
irrelev
complic
potenti
valu
silenc
role
protein
melanoma
role
pathogenesi
prognosi
clinic
melanoma
controversi
protein
found
normal
melanocyt
benign
nevi
primari
melanoma
addit
melanoma
metastas
interestingli
studi
express
decreas
melanoma
cell
vs
normal
melanocyt
howev
find
confirm
studi
minim
differ
express
observ
add
confus
advanc
melanoma
onethird
data
suggest
increas
express
onethird
suggest
decreas
although
function
protein
actual
serv
rather
amount
protein
present
would
probabl
import
howev
one
studi
insuffici
power
demonstr
lymph
node
deposit
express
advanc
melanoma
patient
poorer
prognosi
toto
conflict
data
render
role
advanc
melanoma
unclear
dacarbazin
dtic
approv
chemotherapi
drug
advanc
combin
oblimersen
phase
iii
trial
n
patient
advanc
diseas
oblimersen
administ
via
continu
iv
infus
day
month
initi
dose
mgkgday
increas
dose
maximum
mgkgday
dacarbazin
given
iv
day
six
patient
also
receiv
total
daili
dose
oblimersen
administ
twicedaili
subcutan
inject
day
dacarbazin
iv
day
maximum
decreas
express
patient
biopsi
specimen
highli
variabl
conclus
could
drawn
due
insuffici
sampl
respons
includ
one
cr
two
pr
three
minor
respons
includ
two
patient
whose
diseas
stabil
period
least
year
data
led
initi
largest
phase
iii
trial
advanc
melanoma
date
juli
februari
patient
advanc
melanoma
randomli
assign
receiv
treatment
dacarbazin
alon
iv
min
oblimersen
mgkgday
continu
iv
infus
day
follow
dose
dacarbazin
patient
stratifi
accord
ecog
perform
statu
vs
presenc
absenc
liver
metastasi
diseas
siteserum
ldh
level
latter
categori
includ
two
group
patient
nonviscer
diseas
skin
subcutan
tissu
lymph
node
diseas
normal
ldh
patient
viscer
diseas
exclud
liver
elev
ldh
baselin
serum
level
time
upper
limit
normal
uln
primari
end
point
studi
intenttotreat
itt
comparison
overal
surviv
two
treatment
group
secondari
end
point
includ
progressionfre
surviv
overal
durabl
respons
ie
respons
month
durat
durat
respons
baselin
characterist
group
well
balanc
minimum
followup
month
median
overal
surviv
oblimersendt
group
month
compar
month
dticalon
group
hr
ci
p
overal
respons
rate
cr
pr
patient
treat
oblimersendt
patient
receiv
dtic
alon
p
durabl
respons
also
increas
oblimersendt
group
vs
p
eleven
patient
oblimersendt
group
achiev
cr
comparison
three
patient
dticalon
group
median
surviv
also
significantli
longer
among
patient
receiv
oblimersendt
among
treat
dtic
month
vs
month
hr
p
outcom
data
subsequ
analyz
accord
ldh
stratif
categori
serum
ldh
long
recogn
import
independ
biomark
poor
prognosi
malign
melanoma
studi
interact
treatment
baselin
serum
ldh
observ
patient
ldh
valu
uln
receiv
oblimersendt
approxim
twothird
subject
observ
significantli
better
treatment
efficaci
end
point
includ
overal
surviv
median
month
vs
month
p
progressionfre
surviv
median
month
vs
month
p
overal
respons
vs
p
complet
respons
vs
durabl
respons
vs
p
hand
signific
differ
betweentreat
group
observ
patient
elev
baselin
ldh
ldh
uln
recent
data
demonstr
extent
pretreat
ldh
level
increas
even
within
normal
rang
predict
prognosi
advanc
melanoma
exampl
retrospect
examin
data
obtain
eortc
studi
n
demonstr
monoton
progress
improv
prognosi
advanc
melanoma
patient
valu
ldh
decreas
similar
observ
trial
patient
baselin
ldh
uln
studi
n
median
surviv
month
oblimersendt
group
vs
dtic
group
month
respect
hr
p
confirmatori
trial
agenda
patient
similar
design
studi
doubleblind
design
limit
patient
baselin
ldh
uln
current
ongo
recruit
expect
complet
earli
result
studi
provid
import
prospect
confirmatori
data
previous
discuss
observ
trial
overal
prognosi
advanc
melanoma
depend
pretreat
level
serum
ldh
ldh
ubiquit
enzym
express
frequent
elev
neoplast
cell
shift
glycolysi
secondari
rel
poor
vascular
diminish
oxygen
deliveri
cell
die
via
process
necrosi
releas
ldh
ldh
commonli
releas
apoptosi
tumor
cell
surviv
rate
necrosi
tumor
cell
may
often
depend
balanc
rate
prolifer
vs
rate
vascular
grow
tumor
therefor
possibl
high
ldh
level
patient
may
reflect
diseas
still
grow
least
part
poorli
vascular
type
tumor
frequent
highli
resist
chemotherapi
due
poor
oxygen
deliveri
well
possibl
poor
drug
deliveri
henc
lack
respons
treatment
hypoxia
ultim
import
surviv
factor
tumor
cell
exampl
hypoxia
induc
genet
instabl
select
tumor
cell
increas
metastat
potenti
via
cmet
protooncogen
activ
lead
cell
aggress
invas
diminish
blood
flow
low
ph
also
compromis
function
tumorinfiltr
immun
effector
cell
cytokin
clinic
studi
demonstr
presenc
hypox
region
within
tumor
correl
poor
prognosi
increas
metastat
risk
regardless
treatment
viz
observ
advanc
melanoma
thu
tumor
hypoxia
lead
necrosi
thu
spillag
ldh
also
ultim
aggress
tumor
poorer
prognosi
idea
predict
size
tumor
critic
factor
either
serum
ldh
level
prognosi
trial
rather
balanc
oxygen
suppli
tumor
intrins
growth
rate
critic
trial
neutropenia
thrombocytopenia
signific
advers
effect
associ
increas
seriou
infect
bleed
oblimersendt
group
incid
grade
neutropenia
infect
combin
vs
dtic
alon
grade
bleed
event
primarili
epistaxi
hematuria
also
increas
combinationtreat
group
observ
dtic
group
grade
bleed
event
mostli
gastrointestin
occur
dtic
vs
rate
substanti
lower
associ
drug
drug
regimen
use
treatment
advanc
melanoma
increas
rate
catheterrel
event
venou
thrombosi
infect
occlus
observ
oblimersendt
group
vs
lower
rate
advers
event
result
treatment
discontinu
death
seriou
advers
event
observ
patient
without
elev
baselin
ldh
valu
oblimersen
ad
regimen
etoposid
carboplatin
random
trial
assess
patient
smallcel
lung
cancer
cycl
patient
one
group
receiv
oblimersen
mgkgday
day
carboplatin
day
etoposid
day
patient
control
group
receiv
carboplatin
etoposid
regimen
begin
day
cycl
treatment
group
balanc
respect
baselin
characterist
respons
rate
nearli
ident
two
treatment
group
surviv
year
actual
wors
oblimersen
ci
without
oblimersen
ci
incid
grade
hematolog
toxic
also
somewhat
increas
addit
oblimersen
vs
p
author
offer
sever
possibl
explan
lack
improv
efficaci
oblimersencontain
regimen
one
plausibl
explan
oblimersen
adequ
suppress
level
patient
smallcel
lung
cancer
demonstr
phase
studi
undertaken
determin
regimen
phase
ii
studi
acut
myelogen
leukemia
aml
express
may
contribut
lower
cr
rate
shorter
patient
surviv
phase
studi
marcucci
et
al
enrol
untreat
patient
aml
patient
year
age
either
intermedi
advers
cytogenet
initi
receiv
induct
therapi
oblimersen
mgkgday
continu
iv
infus
day
cytarabin
continu
iv
infus
day
daunorubicin
iv
one
two
dose
day
cr
achiev
patient
incomplet
remiss
achiev
three
patient
level
normal
mrna
express
bone
marrow
mononuclear
cell
found
decreas
baselin
p
patient
cr
increas
baselin
p
nonrespond
patient
express
protein
bone
marrow
mononuclear
cell
h
oblimersen
demonstr
small
signific
decreas
p
patient
cr
vs
nonrespond
patient
howev
given
recent
data
gymnot
ie
nake
deliveri
oligonucleotid
cell
slow
process
requir
day
produc
antisens
effect
possibl
h
insuffici
long
time
point
meaning
measur
protein
patient
develop
pancytopenia
toxic
independ
daunorubicin
dose
well
revers
andor
directli
attribut
oblimersen
phase
ii
trial
oblimersen
gemtuzumab
ozogamicin
mylotarg
human
monoclon
antibodi
conjug
calicheamicin
perform
patient
year
age
aml
first
relaps
oblimersen
mgkgday
administ
continu
iv
infus
day
gemtuzumab
given
iv
day
total
patient
enrol
center
studi
eventu
termin
due
slow
accrual
base
itt
analysi
five
patient
achiev
cr
seven
patient
achiev
cr
without
platelet
recoveri
crp
overal
itt
respons
rate
find
similar
previous
report
singleag
mylotarg
favor
patient
popul
cr
crp
patient
median
relapsefre
surviv
month
ci
month
median
surviv
reach
month
probabl
surviv
month
cr
crp
nonrespond
patient
respect
total
patient
withdrew
complet
therapi
common
reason
toxic
patient
patient
die
within
day
last
dose
studi
medic
five
treatment
toxic
nausea
common
nonhematolog
event
patient
febril
neutropenia
common
hematolog
event
patient
phase
iii
trial
calgb
untreat
older
patient
aml
random
induct
treatment
cytosin
arabinosid
daunorubicin
follow
highdos
cytarabin
consolid
therapi
without
oblimersen
mgkgday
day
induct
day
consolid
show
differ
cr
rate
overal
surviv
diseasefre
surviv
toxic
trial
oblimersen
aml
plan
anoth
hematolog
malign
oblimersen
success
phase
iii
multipl
myeloma
phase
ii
trial
patient
relaps
prior
chemotherapi
transplant
receiv
oblimersen
mgkgday
day
continu
iv
infus
day
patient
receiv
dexamethason
mg
oral
day
thalidomid
mgday
increas
mgday
toler
studi
durat
respond
stabl
patient
receiv
mainten
dose
year
cycl
repeat
everi
day
total
patient
histor
combin
dexamethason
thalidomid
respons
includ
two
cr
four
near
cr
pr
six
minor
respons
median
durat
respons
month
median
overal
surviv
month
rise
polyclon
igm
median
mgdl
found
predict
respons
suggest
due
immunostimul
oligonucleotid
seven
assess
patient
three
demonstr
decreas
protein
malign
cell
correl
protein
level
express
respons
limit
number
patient
grade
toxic
neutropenia
n
thrombocytopenia
n
infect
n
hypocalcemia
n
grade
event
limit
neutropenia
four
patient
increas
serum
creatinin
one
patient
dose
scheme
phase
ii
trial
pursu
instead
random
multin
phase
iii
trial
dexamethason
mgday
oral
day
week
cycl
week
cycl
oblimersen
mgkgday
continu
intraven
infus
begin
day
dexamethason
treatment
week
cycl
week
cycl
conduct
total
patient
relaps
refractori
diseas
primari
end
point
comparison
time
diseas
progress
two
group
baselin
imbal
observ
treatment
group
sever
import
prognost
factor
ecog
perform
statu
baselin
significantli
wors
oblimersendexamethason
group
p
addit
patient
oblimersen
dexamethason
group
categor
stage
iii
iiia
iiib
diseas
dexamethason
group
vs
respect
imbal
two
group
baselin
laboratori
paramet
also
suggest
patient
oblimersendexamethason
group
serious
impair
dexamethason
group
anc
respect
platelet
count
respect
creatinin
mgdl
respect
lactat
dehydrogenas
uln
respect
statist
signific
differ
group
time
tumor
progress
oblimersendexamethason
regimen
gener
well
toler
fatigu
fever
nausea
commonli
observ
advers
event
failur
show
advantag
standard
treatment
dexamethason
may
attribut
signific
differ
betweentreat
group
baselin
favor
dexamethason
group
andor
fact
mani
patient
heavili
pretreat
popul
refractori
dexamethason
oligonucleotid
target
mrna
clusterin
antiapoptot
protein
appar
promot
chemo
radioresist
inhibit
function
proapoptot
bax
protein
compound
phosphorothio
backbon
modifi
presenc
moe
substitu
four
termin
ribos
sugar
moieti
moe
modif
appear
dramat
increas
tissu
halflif
oligom
part
increas
stabil
vs
nucleas
also
evid
moe
gapmer
may
fewer
offtarget
effect
addit
diminish
immunostimulatori
properti
phase
studi
combin
docetaxel
serum
clusterin
level
mg
dose
group
declin
approxim
cycl
howev
declin
clusterin
express
peripher
blood
mononuclear
cell
could
assess
wide
variabl
pretreat
trial
follow
random
phase
ii
trial
plu
docetaxel
vs
docetaxel
plu
prednison
chemotherapyna
patient
metastat
hormonerefractori
prostat
cancer
eightytwo
patient
center
random
arm
docetaxel
dose
dose
mg
initi
patient
toxic
due
includ
grade
fever
rigor
patient
respect
base
recent
press
report
oncogenex
median
surviv
patient
arm
month
month
control
arm
certainli
encourag
signal
respect
proceed
larg
phase
iii
random
trial
indic
ap
antisens
ps
oligonucleotid
target
mrna
justif
target
import
anticanc
target
previous
made
hau
et
al
brief
wide
overexpress
human
tumor
neg
correl
prognosi
protein
block
prolifer
cytotox
activ
nk
cell
potent
immunosuppress
time
act
glioma
growth
angiogen
factor
howev
similar
oblimersen
stori
unclear
extent
vivo
mechan
action
ap
relat
observ
earli
phase
iii
trial
drug
deliv
convectionenhanc
deliveri
directli
tumor
patient
grade
anaplast
astrocytoma
grade
glioblastoma
multiform
diseas
via
implant
cathet
either
four
seven
day
continu
anoth
trial
multipl
cycl
drug
administ
twentyfour
patient
enrol
receiv
total
cycl
mani
patient
pretreat
temozolamid
seven
show
stabl
diseas
day
one
patient
cr
one
cycl
ap
without
therapi
second
patient
receiv
total
cycl
also
cr
still
remiss
year
treatmentrel
death
grade
event
catheterrel
infect
observ
two
advers
event
grade
mtd
reach
dose
escal
plasma
level
ap
intracerebr
infus
limit
detect
laboratori
abnorm
observ
one
seriou
event
brain
edema
consid
possibl
drug
relat
told
drug
appear
extrem
well
toler
phase
iib
intern
openlabel
trial
patient
highgrad
glioma
design
compar
low
high
dose
ap
vs
standard
chemotherapi
temozolamid
procarbazin
lomustin
vincristin
test
drug
administ
weekli
via
convectionenhanc
deliveri
month
six
seriou
advers
event
possibl
relat
studi
drug
procedurerel
seriou
advers
event
grade
report
sever
longterm
tumor
respons
observ
local
mri
read
respons
rate
central
read
yet
present
knowledg
molecul
ps
oligonucleotid
target
untransl
region
pkca
mrna
whose
translat
product
believ
import
signal
transduct
protein
compound
evalu
sever
phase
phase
ii
trial
total
patient
nonsmallcel
lung
cancer
receiv
cisplatin
either
gemcitibin
affinitak
mgkgday
day
via
continu
iv
infus
repeat
everi
week
sixteen
evalu
patient
achiev
respons
cr
pr
median
overal
durat
respons
month
ci
month
median
durat
stabl
diseas
month
ci
month
base
data
larg
multicent
random
phase
iii
trial
nonsmallcel
lung
cancer
perform
detail
trial
appar
publish
understood
affinitak
add
anyth
gemcitibin
cisplatin
combin
longer
clinic
pursu
result
phase
iii
studi
oblimersen
melanoma
cll
multipl
myeloma
suggest
oblimersen
may
activ
patient
advanc
diseas
receiv
multipl
prior
chemotherapi
regimen
despit
evid
clinic
benefit
point
understand
mechan
action
oblimersen
date
clinic
activ
anticanc
antisens
oligonucleotid
far
complet
littl
consequ
advanc
cancer
patient
far
optim
situat
view
antisens
platform
technolog
mean
oblimersen
oneoff
clinic
odditi
repeat
increas
duplex
inclus
lna
lead
improv
clinic
efficaci
recent
advanc
understand
uptak
oligonucleotid
cancer
cell
suggest
improv
dose
schedul
sirna
clean
activ
anticanc
agent
distribut
effici
target
cell
larg
number
question
need
answer
believ
addit
signific
clinic
advanc
achiev
ration
complet
understand
fundament
properti
highli
pleiotrop
biolog
activ
compound
field
oligonucleotidebas
therapi
experienc
reviv
discoveri
rna
interfer
rnai
rnai
conserv
endogen
mechan
trigger
doublestrand
ds
rna
lead
targetspecif
inhibit
gene
express
promot
mrna
degrad
translat
repress
two
rnai
pathway
guid
either
smallinterf
rna
sirna
perfectli
complementari
mrna
microrna
mirna
bind
imperfectli
target
mrna
breakthrough
field
sirna
therapeut
agent
achiev
elbashir
et
al
demonstr
synthet
exogen
appli
dsrna
nucleotid
length
induc
silenc
mammalian
cell
addit
sirna
design
duplex
side
dicersubstr
format
short
hairpin
sh
rna
develop
elicit
potent
genesilenc
effect
lower
concentr
compar
convent
sirna
remark
quickli
discoveri
rnai
establish
method
choic
target
inhibit
gene
express
mammalian
system
rnai
use
natur
pathway
gene
silenc
gener
result
greater
potenc
knockdown
antisens
oligonucleotid
ribozym
preclin
result
confirm
effect
rnai
gener
seriou
optim
potenti
sirna
drug
oligonucleotidebas
approach
applic
sirna
therapeut
agent
face
mention
challeng
challeng
howev
alreadi
address
cours
antisens
oligonucleotid
ribozym
develop
mani
standard
stabil
oligonucleotid
modif
alreadi
explor
antisens
strategi
employ
sirna
design
sirna
properti
benefici
improv
introduct
certain
chemic
modif
distinct
posit
sequenc
includ
thermal
stabil
duplex
resist
degrad
specif
target
mrna
reduct
offtarget
effect
biodistribut
cellular
uptak
systemat
studi
jackson
cowork
report
mani
individu
nucleotid
antisens
strand
may
modifi
group
without
loss
silenc
potenti
similar
studi
perform
addit
advantag
use
nucleotid
reduct
offtarget
effect
well
avoid
interferon
respons
strateg
placement
modif
crucial
modif
guid
strand
inhibit
silenc
effect
modif
passeng
strand
improv
stabil
well
guid
strand
select
target
specif
incorpor
boranophosph
lna
also
report
enhanc
targetbind
affin
increas
silenc
potenc
preclin
studi
demonstr
safe
use
potenti
benefit
rnaimedi
gene
silenc
sirna
earlystag
clinic
trial
treatment
viral
infect
cancer
ocular
diseas
phase
studi
plan
numer
diseas
includ
neurodegen
diseas
asthmaallergi
inflammatori
diseas
advancedstag
test
sirnabas
drug
treatment
viral
infect
develop
alnylam
pharmaceut
cambridg
usa
sirna
design
respiratori
syncyti
viru
rsv
caus
sever
respiratori
ill
primarili
infant
unmodifi
sirna
administ
inhal
show
signific
viral
reduct
experiment
infect
adult
volunt
compar
placebo
group
phase
ii
gemini
studi
test
patient
natur
acquir
rsv
infect
exampl
antivir
applic
propos
sever
acut
respiratori
syndrom
sar
herp
simplex
viru
seriou
concern
rapid
develop
drugresist
hiv
variant
make
use
multipledrug
combin
inevit
recent
pilot
studi
safeti
feasibl
stem
cell
therapi
lymphoma
patient
aid
initi
use
lentiviru
vector
encod
three
antihiv
rna
combinatori
approach
involv
shrna
target
tatrev
rna
tar
decoy
antichemokin
receptor
ribozym
lead
product
intradigm
palo
alto
ca
usa
target
angiogenesi
http
wwwintradigmcom
rnai
nanoplex
particl
compris
nanoparticl
two
sirna
one
vascular
endotheli
growth
factor
vegf
vegf
main
receptor
product
preclin
develop
varieti
cancer
indic
compani
expect
initi
clinic
evalu
two
ongo
clinic
trial
also
aim
angiogenesi
agerel
macular
defici
amd
bevasiranib
previous
known
develop
vegf
agn
previous
known
receptor
earli
clinic
studi
show
therapeut
reagent
well
toler
could
prevent
neovascular
eye
intravitr
inject
agn
investig
phase
ii
studi
combin
ranibizumab
patient
current
enrol
phase
iii
studi
evalu
safeti
effect
bevasiranib
controversi
report
recent
publish
suggest
suppress
neovascular
two
anim
model
gener
properti
sirna
activ
independ
sequenc
exampl
clearli
demonstr
preclin
studi
need
care
conduct
prove
safeti
specif
sirnamedi
silenc
effect
encourag
earlier
achiev
oligonucleotidebas
therapeut
rnai
strategi
may
rush
clinic
trial
crucial
understand
basic
mechan
rnai
divers
relat
effector
avoid
toxic
side
effect
develop
ration
design
biopharmaceut
